scholarly journals Selection of Human Single Domain Antibodies (sdAb) Against Thymidine Kinase 1 and Their Incorporation Into sdAb-Fc Antibody Constructs For Potential Use In Cancer Therapy.

Author(s):  
Edwin J Velazquez ◽  
Jordan D Cress ◽  
Tyler B Humpherys ◽  
Toni O Mortimer ◽  
David M Bellini ◽  
...  

Thymidine Kinase 1 (TK1) is primarily known as a cancer biomarker with good prognostic capabilities for liquid and solid malignancies. However, recent studies targeting TK1 at protein and mRNA levels have shown that TK1 may be useful as a tumor target. In order to examine the use of TK1 as a tumor target, it is necessary to develop therapeutics specific for TK1. Single domain antibodies (sdAbs), represent an exciting approach for the development of immunotherapeutics due to their cost-effective production and higher tumor penetration than conventional antibodies. In this study, we isolated sdAb fragments specific to human TK1 from a human sdAb library. A total of 400 sdAbs were screened through 5 rounds of selection by monoclonal phage ELISA. The most sensitive sdAb fragments were selected as candidates for preclinical testing. The sdAb fragments showed specificity for human TK1 in phage ELISA, Western blot analysis and had a limit of detection of 3.9 ng/ml for 4-H-TK1_A1 and 1.9 ng/ml for 4-H-TK1_D1. The antibody fragments were successfully expressed and used for detection of membrane associated TK1 (mTK1) through flow cytometry on cancer cells [lung (~95%), colon (~87%), breast (~53%)] and healthy human mono nuclear cells (MNC). The most sensitive antibody fragments, 4-H-TK1_A1 and 4-H-TK1_D1 were fused to an engineered IgG1 Fc fragment. When added to cancer cells expressing mTK1 co-cultured with human MNC, the anti-TK1-sdAb-IgG1_A1 and D1 were able to elicit a significant antibody-dependent cell-mediated cytotoxicity (ADCC) response by human MNCs against lung cancer cells compared to isotype controls (P<0.0267 and P<0.0265, respectively). To our knowledge this is the first time that the isolation and evaluation of human anti TK1 single domain antibodies using phage display technology has been reported. The antibody fragments isolated here may represent a valuable resource for the detection and the targeting of TK1 in tumor cells

Antibodies ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 27 ◽  
Author(s):  
Kasandra Bélanger ◽  
Umar Iqbal ◽  
Jamshid Tanha ◽  
Roger MacKenzie ◽  
Maria Moreno ◽  
...  

Antibodies have become one of the most successful therapeutics for a number of oncology and inflammatory diseases. So far, central nervous system (CNS) indications have missed out on the antibody revolution, while they remain ‘hidden’ behind several hard to breach barriers. Among the various antibody modalities, single-domain antibodies (sdAbs) may hold the ‘key’ to unlocking the access of antibody therapies to CNS diseases. The unique structural features of sdAbs make them the smallest monomeric antibody fragments suitable for molecular targeting. These features are of particular importance when developing antibodies as modular building blocks for engineering CNS-targeting therapeutics and imaging agents. In this review, we first introduce the characteristic properties of sdAbs compared to traditional antibodies. We then present recent advances in the development of sdAbs as potential therapeutics across brain barriers, including their use for the delivery of biologics across the blood–brain and blood–cerebrospinal fluid (CSF) barriers, treatment of neurodegenerative diseases and molecular imaging of brain targets.


2016 ◽  
Author(s):  
Evita G. Weagel ◽  
Roger P. Chu ◽  
Wei Meng ◽  
Rachel A. Brog ◽  
Michelle H. Townsend ◽  
...  

2020 ◽  
Author(s):  
Edwin J. Velazquez ◽  
Jordan D. Cress ◽  
Kathryn R. Smith ◽  
David M. Bellini ◽  
Jonathan R. Skidmore ◽  
...  

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Edwin J. Velazquez ◽  
Taylor D. Brindley ◽  
Gajendra Shrestha ◽  
Eliza E. Bitter ◽  
Jordan D. Cress ◽  
...  

2016 ◽  
Author(s):  
Evita G. Weagel ◽  
Rachel A. Brog ◽  
Michelle H. Townsend ◽  
Edwin J. Velazquez ◽  
Toshiko A. Becker ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document